Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Feng Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8790-6072; OpenAlex author ID A5031349337. Sources: OpenAlex.

Their work

Papers
20 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 4 papers · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 20

  1. Burdens of pancreatic cancer from 1990 to 2021 and projection to 2050 in China: findings from the 2021 global burden of disease study. Co-author DOI 10.1186/s12885-026-16616-9↗
  2. Periarterial divestment for borderline and locally advanced pancreatic cancer: An analysis of 125 cases in a single center. Co-author DOI 10.1016/j.surg.2025.109412↗
  3. The development and validation of biomarkers-based scoring systems for predicting early recurrence in patients with borderline resectable pancreatic cancer und… Co-author DOI 10.21037/gs-2024-500↗
  4. Recurrence scoring system predicting early recurrence for patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy and portomesenteric vein res… Co-author DOI 10.4240/wjgs.v16.i10.3185↗
  5. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.medj.2023.07.010↗
  6. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Co-author DOI 10.1038/s41392-021-00659-4↗
  7. The construction and analysis of a ferroptosis-related gene prognostic signature for pancreatic cancer. First author DOI 10.18632/aging.202801↗
  8. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. Co-author DOI 10.1038/s41392-020-0146-6↗
  9. A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2019.01160↗
  10. Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges. Co-author DOI 10.3748/wjg.v25.i23.2839↗
  11. Genome-Wide Analysis Identified a Number of Dysregulated Long Noncoding RNA (lncRNA) in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/1533034617748429↗
  12. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival. Co-author DOI 10.1016/s1499-3872(16)60168-6↗
  13. Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein invo… Co-author DOI 10.18632/oncotarget.20847↗
  14. Magnetic graphene-based nanotheranostic agent for dual-modality mapping guided photothermal therapy in regional lymph nodal metastasis of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2014.07.064↗
  15. FOXP3+ lymphocyte density in pancreatic cancer correlates with lymph node metastasis. Co-author DOI 10.1371/journal.pone.0106741↗
  16. Establishment of an orthotopic pancreatic cancer mouse model: cells suspended and injected in Matrigel. Co-author DOI 10.3748/wjg.v20.i28.9476↗
  17. MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1. Co-author DOI 10.4161/cbt.29706↗
  18. Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Co-author DOI 10.1007/s12032-013-0700-y↗
  19. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer. Co-author DOI 10.3892/or.2013.2516↗
  20. Emerging inorganic nanomaterials for pancreatic cancer diagnosis and treatment. Co-author DOI 10.1016/j.ctrv.2012.02.003↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chen Jin · 12 shared papers, 2013–2025 · strength 1.37
  2. Deliang Fu · 14 shared papers, 2012–2024 · strength 1.17
  3. Hang He · 8 shared papers, 2013–2025 · strength 1.04
  4. Yongjian Jiang · 8 shared papers, 2013–2025 · strength 0.77
  5. Dong Xu · 1 shared paper, 2026 · strength 0.43
  6. Qiongzhu Dong · 4 shared papers, 2019–2023 · strength 0.41
  7. Yan Zheng · 4 shared papers, 2019–2023 · strength 0.41
  8. Christiane J. Bruns · 4 shared papers, 2019–2023 · strength 0.41
  9. Yue Zhao · 4 shared papers, 2019–2023 · strength 0.41
  10. Di Yang · 8 shared papers, 2012–2018 · strength 0.39
  11. Deliang Fu · 2 shared papers, 2017–2025 · strength 0.38
  12. Beiyuan Hu · 3 shared papers, 2020–2023 · strength 0.33
  13. Ji Li · 1 shared paper, 2025 · strength 0.30
  14. De-Liang Fu · 1 shared paper, 2025 · strength 0.27
  15. Ji Li · 2 shared papers, 2013–2024 · strength 0.26
  16. Lie Yao · 4 shared papers, 2013–2018 · strength 0.23
  17. Sijie Hao · 3 shared papers, 2013–2018 · strength 0.16
  18. Ji Li · 3 shared papers, 2014–2017 · strength 0.15
  19. Shurui Bu · 1 shared paper, 2021 · strength 0.15
  20. Peicheng Jiang · 1 shared paper, 2021 · strength 0.15
  21. Dongqin Yang · 1 shared paper, 2021 · strength 0.15
  22. Andrew Louis Warshaw · 1 shared paper, 2019 · strength 0.14
  23. Ying Zhu · 1 shared paper, 2023 · strength 0.14
  24. Ze Zhang · 1 shared paper, 2023 · strength 0.14
  25. Bo Tu · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.